Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.
| Revenue (TTM) | $85.53M |
| Gross Profit (TTM) | $49.97M |
| EBITDA | $7.82M |
| Operating Margin | -5.66% |
| Return on Equity | -78.60% |
| Return on Assets | 1.62% |
| Revenue/Share (TTM) | $19.20 |
| Book Value | $2.25 |
| Price-to-Book | 2.48 |
| Price-to-Sales (TTM) | 0.29 |
| EV/Revenue | 0.724 |
| EV/EBITDA | 42.62 |
| Quarterly Earnings Growth (YoY) | -80.30% |
| Quarterly Revenue Growth (YoY) | -4.70% |
| Shares Outstanding | $4.51M |
| Float | $3.50M |
| % Insiders | 7.65% |
| % Institutions | 45.91% |
Volatility is currently expanding